Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alexion | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alexion

Soliris sales up 24% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion

2Q Revenues: $636.2 million (+24%)

2Q Earnings: $170.2 million (+2%)

YTD Revenue: $1.2 billion (+15%)

YTD Earnings: $261.5 million (-20%)

Comments: Solirissales were $636 million in the quarter, up 24%. R&D expenses were $131.7 million compared to $92.6 million in 2Q14. The company closed the Synageva acquisition in the quarter, strengthening its rare diseases portfolio. Strensiq received a positive opinion from the EMA recommending marketing authorization for the long-term enzyme replacement therapy in patients with pediatric-onset HPP. Kanuma also receiveda positive EMA opinion recommending marketing authorization for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics